Invezz
24 Aug 2026, 07:46 UTC · 1h ago
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Invezz
24 Aug 2026, 07:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Citi analyst Yigal Nochomovitz set a $7 price target for Biomea Fusion (BMEA), implying a potential 410% upside. — Such a massive implied upside from a major institution can trigger significant speculative buying and volatility.
+0.80Biomea Fusion is awaiting Phase 1 28-day readout data for its oral GLP-1 obesity candidate BMF-650 in Q3. — Clinical readouts for obesity drugs (GLP-1s) are currently high-impact catalysts that can cause binary price swings.
+0.70Citi set a $57 price target for Syndax Pharmaceuticals (SNDX), implying roughly 190% upside. — A strong bullish target for a revenue-generating company suggests fundamental growth potential.
+0.60Continue reading
6 related stories
Search tags
Syndax Pharmaceuticals reported Q2 revenue growth of 92% year-over-year, driven by sales of Revuforj and Niktimvo. — Strong revenue growth reduces the binary risk typically associated with biotech stocks.
Which stocks this story touches
Citi rates the stock as a Buy with a projected 410% upside ahead of key obesity drug data.
Citi maintains a bullish target based on strong revenue growth and franchise expansion.
Citi is mentioned as the source of the analysis and ratings rather than as a subject of the news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
20h ago
